Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Receivables - Other: 2019-2023

Historic Receivables - Other for BridgeBio Pharma (BBIO) over the last 4 years, with Dec 2023 value amounting to $600,000.

  • BridgeBio Pharma's Receivables - Other fell 90.75% to $478,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $478,000, marking a year-over-year decrease of 90.75%. This contributed to the annual value of $600,000 for FY2023, which is 96.49% down from last year.
  • Per BridgeBio Pharma's latest filing, its Receivables - Other stood at $600,000 for FY2023, which was down 96.49% from $17.1 million recorded in FY2022.
  • Over the past 5 years, BridgeBio Pharma's Receivables - Other peaked at $19.7 million during FY2021, and registered a low of $600,000 during FY2023.
  • Its 3-year average for Receivables - Other is $12.5 million, with a median of $17.1 million in 2022.
  • Data for BridgeBio Pharma's Receivables - Other shows a maximum YoY plummeted of 96.49% (in 2023) over the last 5 years.
  • Over the past 4 years, BridgeBio Pharma's Receivables - Other (Yearly) stood at $2.8 million in 2019, then reached $19.7 million in 2021, then dropped by 13.52% to $17.1 million in 2022, then crashed by 96.49% to $600,000 in 2023.